NCT03608007View on ClinicalTrials.gov

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

PHASE2UnknownINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

September 30, 2020

Conditions
Lung CancerROS1 Gene Rearrangement
Interventions
DRUG

X-396 Capsule

225 mg once daily

Trial Locations (1)

200000

RECRUITING

Chest hospital affiliated to Shanghai jiao tong university, Shanghai

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY